<DOC>
	<DOCNO>NCT00102986</DOCNO>
	<brief_summary>Men 's woman 's body may process anti-HIV drug differently . The purpose study determine difference blood level soft gel capsule tablet lopinavir/ritonavir ( LPV/r ) HIV infect men woman .</brief_summary>
	<brief_title>Differences Blood Levels Lopinavir/Ritonavir HIV Infected Men Women</brief_title>
	<detailed_description>It estimate 50 % people live HIV/AIDS worldwide woman . HIV infect woman face different psychosocial issue men , body may react differently HIV treatment . However , data safety efficacy antiretrovirals ( ARVs ) use treatment HIV infection study conduct primarily men . LPV/r tablet form approve FDA October 2005 . This study determine difference pharmacokinetics ( PK ) men woman take soft gel capsule tablet formulation LPV/r . No ARVs provide study . In Step 1 , participant receive soft gel capsule LPV/r . All Step 1 participant ask join Step 2 study upon completion Step 1 . In Step 2 , participant receive tablet LPV/r . During study , participant Step 1 2 take treatment regimen LPV/r twice daily one following : nucleoside reverse transcriptase inhibitor ( NRTI ) , tenofovir disoproxil fumarate , enfuvirtide . Medical medication history , blood collection , clinical assessment occur study screen Steps 1 2 . Participants step ask complete medication diary study entry day PK visit . The PK visit occur within 30 day study screen ; blood collection PK analysis also occur visit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Note : Step 1 enrollment end 06/28/06 . Inclusion Criteria HIV infect Have take twicedaily LPV/r ( soft gel formulation Step 1 participant tablet formulation Step 2 participant ) least 14 day immediately prior step screen willing continue take LPV/r PK visit step Have take LPV/r combination least one follow least 14 day immediately prior study step screening : zidovudine , lamivudine , emtricitabine , stavudine , abacavir sulfate , didanosine , zalcitabine , tenofovir disoproxil fumarate , enfuvirtide , AND willing continue take PK visit step Body weight 50 kg ( 110 lb ) Step 1 participant Nonnucleoside reverse transcriptase inhibitor dual protease inhibitor regimen within 30 day prior study entry Require certain medication Current drug alcohol abuse , investigator 's opinion , may interfere study Serious illness require systemic treatment hospitalization within 30 day study screen Acute AIDSrelated opportunistic infection within 90 day study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Kaletra</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>